Apollomics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Hung-Wen Chen
- Full Time Employees
- 14
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 989 East Hillsdale Blvd Foster City CA United States of America
- IPO Date
- Mar 30, 2023
- CIK
- 0001944885
- Website
- apollomicsinc.com
- Similar Companies
- Business
- Apollomics, Inc. (NasdaqCM:APLMW) is a clinical-stage biopharmaceutical company focused on the development of mono- and combination-oncology therapies to address difficult-to-treat cancers. The company offers a pipeline of targeted assets, including novel antibody-drug conjugates (ADCs) such as APVO436 (a bispecific T-cell engager targeting CD123 and CD3), APVO471 (a bispecific antibody targeting 4-1BB and CD40), APVO603 (a bispecific antibody targeting PD-1 and LAG-3), and small molecule therapies like APL-501 (a next-generation multi-kinase inhibitor) and APL-102 (a selective CDK7 inhibitor); its lead candidates target acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and solid tumors. Apollomics operates primarily in the oncology segment, serving patients and healthcare providers through clinical trials and partnerships across the United States, Europe, and Asia. Founded in 2015 and headquartered in Morrisville, North Carolina, the company maintains research and development facilities in the U.S. and China, with manufacturing and clinical operations spanning North America, Europe (including the UK), and Asia-Pacific regions. It targets global markets for oncology treatments, emphasizing underserved indications in hematological malignancies and solid tumors. In the last two years, Apollomics has undergone significant strategic shifts, including its initial public offering (IPO) on Nasdaq in 2023 via a business combination with a special purpose acquisition company, enhancing its capital for pipeline advancement. The company expanded its leadership team with key appointments in clinical development and secured collaborations with institutions like the National Cancer Institute for trial support. Additionally, Apollomics reported positive interim data from ongoing Phase 1b/2 trials of APVO436 in AML patients and initiated new combination studies, positioning it for potential regulatory milestones in 2025-2026.
Apollomics Regains Full Compliance with Nasdaq Listing Requirements
Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress
Apollomics Inc. Announces $2.0 Million Bridge Financing
Apollomics Reports First Half 2025 Financial Results
Apollomics Announces Settlement of Cayman Litigation
Apollomics Announces Changes to its Board of Directors and Composition of Committees
Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation
Nasdaq Resumes Trading in Apollomics Inc.
Apollomics, Inc. Company Operational Continuity Update
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
Apollomics Announces Updated Strategic Focus and Leadership Team Changes
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene